Matches in Wikidata for { <http://www.wikidata.org/entity/Q58416764> ?p ?o ?g. }
Showing items 1 to 67 of
67
with 100 items per page.
- Q58416764 description "article" @default.
- Q58416764 description "im Mai 2004 veröffentlichter wissenschaftlicher Artikel" @default.
- Q58416764 description "wetenschappelijk artikel" @default.
- Q58416764 description "наукова стаття, опублікована в травні 2004" @default.
- Q58416764 name "Daily Low-Dose Subcutaneous Interleukin-2 Added To Single- or Dual-Nucleoside Therapy in HIV Infection Does Not Protect Against CD4+ T-Cell Decline or Improve Other Indices of Immune Function: Results of a Randomized Controlled Clinical Trial (ACTG 2" @default.
- Q58416764 name "Daily Low-Dose Subcutaneous Interleukin-2 Added To Single- or Dual-Nucleoside Therapy in HIV Infection Does Not Protect Against CD4+ T-Cell Decline or Improve Other Indices of Immune Function: Results of a Randomized Controlled Clinical Trial" @default.
- Q58416764 type Item @default.
- Q58416764 label "Daily Low-Dose Subcutaneous Interleukin-2 Added To Single- or Dual-Nucleoside Therapy in HIV Infection Does Not Protect Against CD4+ T-Cell Decline or Improve Other Indices of Immune Function: Results of a Randomized Controlled Clinical Trial (ACTG 2" @default.
- Q58416764 label "Daily Low-Dose Subcutaneous Interleukin-2 Added To Single- or Dual-Nucleoside Therapy in HIV Infection Does Not Protect Against CD4+ T-Cell Decline or Improve Other Indices of Immune Function: Results of a Randomized Controlled Clinical Trial" @default.
- Q58416764 prefLabel "Daily Low-Dose Subcutaneous Interleukin-2 Added To Single- or Dual-Nucleoside Therapy in HIV Infection Does Not Protect Against CD4+ T-Cell Decline or Improve Other Indices of Immune Function: Results of a Randomized Controlled Clinical Trial (ACTG 2" @default.
- Q58416764 prefLabel "Daily Low-Dose Subcutaneous Interleukin-2 Added To Single- or Dual-Nucleoside Therapy in HIV Infection Does Not Protect Against CD4+ T-Cell Decline or Improve Other Indices of Immune Function: Results of a Randomized Controlled Clinical Trial" @default.
- Q58416764 P1433 Q58416764-0F11D6E5-DE45-456F-8283-72AABA781826 @default.
- Q58416764 P1476 Q58416764-EAACAF76-C5D5-4553-BFA0-E334EF2CB952 @default.
- Q58416764 P2093 Q58416764-1C7C2F69-944E-48B2-8ADE-E169B003A371 @default.
- Q58416764 P2093 Q58416764-2A7ACD8E-0D9C-4E30-B624-CD11151FB3EC @default.
- Q58416764 P2093 Q58416764-2C0588F2-7A58-4DC0-93E3-B8468A4CA34D @default.
- Q58416764 P2093 Q58416764-58AD0F5A-B135-477F-8C68-CA76EE92D600 @default.
- Q58416764 P2093 Q58416764-58F222FC-4AE0-4018-904B-98C35B89D71E @default.
- Q58416764 P2093 Q58416764-72A57DA1-4321-4F63-9F2D-CEE14055BEA5 @default.
- Q58416764 P2093 Q58416764-8643AC67-3DA6-4B5E-8326-A22F841EF070 @default.
- Q58416764 P2093 Q58416764-91CFFD16-B245-4865-B228-7702E57513FA @default.
- Q58416764 P2093 Q58416764-98D67A8A-99C2-4900-ACC1-ABA8E209C02A @default.
- Q58416764 P2093 Q58416764-A0018A28-777B-4FEB-B645-F558C092FA2D @default.
- Q58416764 P2093 Q58416764-A5A9BD00-56F6-430B-BA18-EB26FA481DFF @default.
- Q58416764 P2093 Q58416764-C001492A-F863-4C43-8449-2852DA0BCCC3 @default.
- Q58416764 P2093 Q58416764-DE2B946B-646B-4855-AA3B-5E66D0E4D982 @default.
- Q58416764 P304 Q58416764-DB295BE7-4AA2-42C9-B79A-89B3FA2CF49B @default.
- Q58416764 P31 Q58416764-242DACAB-9841-43D5-8415-E7F6BDB971B3 @default.
- Q58416764 P356 Q58416764-A80DC793-7C13-44F7-99DE-BE91A16001D8 @default.
- Q58416764 P407 Q58416764-7F0A7BC3-0A6A-4711-B73C-FC88868FEDE8 @default.
- Q58416764 P433 Q58416764-CC92FF8A-ACB7-42FA-8C0B-3985EDDBD613 @default.
- Q58416764 P478 Q58416764-9075AF15-8AFA-4F61-9149-D020E29D92EC @default.
- Q58416764 P50 Q58416764-0DEC9A72-FA6B-45D5-9E2D-73EAEFAB6496 @default.
- Q58416764 P50 Q58416764-DEE5C712-8009-440A-9952-62903E177C6D @default.
- Q58416764 P577 Q58416764-80AAF620-2618-4261-BA02-A5FAB40D4EE1 @default.
- Q58416764 P698 Q58416764-1FC6CC49-B944-4294-B20A-A0E6C627FC4B @default.
- Q58416764 P921 Q58416764-6779331C-E132-41E8-AE77-9D180C257AA2 @default.
- Q58416764 P921 Q58416764-eec4bf1e-b778-43b4-abde-cec274d2d8c2 @default.
- Q58416764 P356 00126334-200405010-00005 @default.
- Q58416764 P698 15097300 @default.
- Q58416764 P1433 Q6294722 @default.
- Q58416764 P1476 "Daily low-dose subcutaneous interleukin-2 added to single- or dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248)" @default.
- Q58416764 P2093 "AIDS Clinical Trials Group 248 Study Team" @default.
- Q58416764 P2093 "Barbara Schock" @default.
- Q58416764 P2093 "Charles J Gonzalez" @default.
- Q58416764 P2093 "Deborah Weng Cherng" @default.
- Q58416764 P2093 "Donna Mildvan" @default.
- Q58416764 P2093 "Hedy Teppler" @default.
- Q58416764 P2093 "Ian Frank" @default.
- Q58416764 P2093 "Kathleen E Squires" @default.
- Q58416764 P2093 "Laura F Mahon" @default.
- Q58416764 P2093 "Mary A Vogler" @default.
- Q58416764 P2093 "Michael M Lederman" @default.
- Q58416764 P2093 "Rebecca Gelman" @default.
- Q58416764 P2093 "Richard B Pollard" @default.
- Q58416764 P304 "576-587" @default.
- Q58416764 P31 Q13442814 @default.
- Q58416764 P356 "10.1097/00126334-200405010-00005" @default.
- Q58416764 P407 Q1860 @default.
- Q58416764 P433 "1" @default.
- Q58416764 P478 "36" @default.
- Q58416764 P50 Q118469506 @default.
- Q58416764 P50 Q42536867 @default.
- Q58416764 P577 "2004-05-01T00:00:00Z" @default.
- Q58416764 P698 "15097300" @default.
- Q58416764 P921 Q124683452 @default.
- Q58416764 P921 Q194908 @default.